Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 26 |
| List of Tables | 24 | 3 |
| List of Figures | 27 | 1 |
| Introduction | 28 | 1 |
| Global Markets Direct Report Coverage | 28 | 1 |
| Hepatitis C Overview | 29 | 1 |
| Therapeutics Development | 30 | 2 |
| Pipeline Products for Hepatitis C Overview | 30 | 1 |
| Pipeline Products for Hepatitis C Comparative Analysis | 31 | 1 |
| Hepatitis C Therapeutics under Development by Companies | 32 | 7 |
| Hepatitis C Therapeutics under Investigation by Universities/Institutes | 39 | 3 |
| Hepatitis C Pipeline Products Glance | 42 | 4 |
| Late Stage Products | 42 | 1 |
| Clinical Stage Products | 43 | 1 |
| Early Stage Products | 44 | 1 |
| Unknown Stage Products | 45 | 1 |
| Hepatitis C Products under Development by Companies | 46 | 11 |
| Hepatitis C Products under Investigation by Universities/Institutes | 57 | 2 |
| Hepatitis C Companies Involved in Therapeutics Development | 59 | 76 |
| 3-V Biosciences, Inc. | 59 | 1 |
| AbbVie Inc | 60 | 1 |
| AIMM Therapeutics B.V. | 61 | 1 |
| Akshaya Bio Inc. | 62 | 1 |
| Amarillo Biosciences, Inc. | 63 | 1 |
| Amarna Therapeutics B.V. | 64 | 1 |
| ARA Healthcare Pvt. Ltd. | 65 | 1 |
| Aviragen Therapeutics, Inc. | 66 | 1 |
| Beijing Kawin Technology Share-Holding Co., Ltd. | 67 | 1 |
| Benitec Biopharma Limited | 68 | 1 |
| Beta Pharma, Inc. | 69 | 1 |
| Biogenomics Limited | 70 | 1 |
| BioLineRx, Ltd. | 71 | 1 |
| Bionor Pharma ASA | 72 | 1 |
| Biotest AG | 73 | 1 |
| Biotron Limited | 74 | 1 |
| Boehringer Ingelheim GmbH | 75 | 1 |
| Bolder Biotechnology, Inc. | 76 | 1 |
| Bristol-Myers Squibb Company | 77 | 1 |
| Chugai Pharmaceutical Co., Ltd. | 78 | 1 |
| Cocrystal Pharma, Inc. | 79 | 1 |
| Conatus Pharmaceuticals Inc. | 80 | 1 |
| ContraVir Pharmaceuticals, Inc. | 81 | 1 |
| DEKK-TEC, Inc. | 82 | 1 |
| Delpor, Inc. | 83 | 1 |
| Digna Biotech, S.L. | 84 | 1 |
| Enanta Pharmaceuticals, Inc. | 85 | 1 |
| F. Hoffmann-La Roche Ltd. | 86 | 1 |
| Formune S.L. | 87 | 1 |
| Genecode AS | 88 | 1 |
| GeneCure LLC | 89 | 1 |
| Gilead Sciences, Inc. | 90 | 1 |
| GinkgoPharma Co. Ltd. | 91 | 1 |
| GlaxoSmithKline Plc | 92 | 1 |
| HanAll Biopharma Co., Ltd. | 93 | 1 |
| HEC Pharm Co., Ltd. | 94 | 1 |
| ImmunoBiology Limited | 95 | 1 |
| Inovio Pharmaceuticals, Inc. | 96 | 1 |
| Integrated BioTherapeutics, Inc. | 97 | 1 |
| JN-International Medical Corporation | 98 | 1 |
| Johnson &Johnson | 99 | 1 |
| Karyopharm Therapeutics, Inc. | 100 | 1 |
| Kineta, Inc. | 101 | 1 |
| LG Life Science LTD. | 102 | 1 |
| Ligand Pharmaceuticals, Inc. | 103 | 1 |
| Medivir AB | 104 | 1 |
| Merck &Co., Inc. | 105 | 1 |
| Microbio Co., Ltd. | 106 | 1 |
| Microbiotix, Inc. | 107 | 1 |
| MultiCell Technologies, Inc. | 108 | 1 |
| NeuroVive Pharmaceutical AB | 109 | 1 |
| Novartis AG | 110 | 1 |
| NovaTarg Therapeutics, Inc | 111 | 1 |
| Ono Pharmaceutical Co., Ltd. | 112 | 1 |
| Pfenex Inc. | 113 | 1 |
| Pfizer Inc. | 114 | 1 |
| PharmaEssentia Corporation | 115 | 1 |
| Polaris Pharmaceuticals, Inc. | 116 | 1 |
| Presidio Pharmaceuticals, Inc. | 117 | 1 |
| Profectus BioSciences, Inc. | 118 | 1 |
| Regulus Therapeutics Inc. | 119 | 1 |
| REPLICor Inc. | 120 | 1 |
| Rodos BioTarget GmbH | 121 | 1 |
| Savoy Pharmaceuticals, Inc. | 122 | 1 |
| SomaGenics, Inc. | 123 | 1 |
| Sorrento Therapeutics, Inc. | 124 | 1 |
| Spring Bank Pharmaceuticals, Inc. | 125 | 1 |
| TaiGen Biotechnology Co., Ltd. | 126 | 1 |
| TaiwanJ Pharmaceuticals Co., Ltd. | 127 | 1 |
| TGV-Laboratories | 128 | 1 |
| Therapix Biosciences Ltd. | 129 | 1 |
| Therapure Biopharma Inc. | 130 | 1 |
| Vakzine Projekt Management GmbH | 131 | 1 |
| Vertex Pharmaceuticals Incorporated | 132 | 1 |
| WhanIn Pharmaceutical Co., Ltd. | 133 | 1 |
| Zylacta Corporation | 134 | 1 |
| Hepatitis C Therapeutics Assessment | 135 | 20 |
| Assessment by Monotherapy Products | 135 | 1 |
| Assessment by Combination Products | 136 | 1 |
| Assessment by Target | 137 | 7 |
| Assessment by Mechanism of Action | 144 | 7 |
| Assessment by Route of Administration | 151 | 2 |
| Assessment by Molecule Type | 153 | 2 |
| Drug Profiles | 155 | 320 |
| (AL-335 + odalasvir + simeprevir) Drug Profile | 155 | 2 |
| (danoprevir + ritonavir) Drug Profile | 157 | 1 |
| (dasabuvir + ombitasvir + paritaprevir + ritonavir) ER Drug Profile | 158 | 1 |
| (grazoprevir + ruzasvir + uprifosbuvir) Drug Profile | 159 | 2 |
| (hydroxychloroquine + ribavirin) Drug Profile | 161 | 2 |
| (ombitasvir + paritaprevir + ritonavir) + dasabuvir Drug Profile | 163 | 2 |
| (sofosbuvir + velpatasvir + voxilaprevir) Drug Profile | 165 | 2 |
| (sofosbuvir + velpatasvir) Drug Profile | 167 | 5 |
| ACH-3422 Drug Profile | 172 | 2 |
| AL-335 Drug Profile | 174 | 2 |
| AL-516 Drug Profile | 176 | 1 |
| alisporivir + EDP-239 Drug Profile | 177 | 1 |
| Antisense RNAi Oligonucleotide to Inhibit miR-122 for Hepatitis C Drug Profile | 178 | 1 |
| ARABS-3 Drug Profile | 179 | 1 |
| ARABS-4 Drug Profile | 180 | 1 |
| ARABS-5 Drug Profile | 181 | 1 |
| asunaprevir + daclatasvir dihydrochloride Drug Profile | 182 | 2 |
| AV-4025 Drug Profile | 184 | 2 |
| AV-4203 Drug Profile | 186 | 1 |
| AVR-560 Drug Profile | 187 | 1 |
| BBT-012 Drug Profile | 188 | 1 |
| beclabuvir hydrochloride Drug Profile | 189 | 1 |
| BH-6870 Drug Profile | 190 | 1 |
| BI-207524 Follow-Up Drug Profile | 191 | 1 |
| BIP-48 Drug Profile | 192 | 1 |
| BIT-225 Drug Profile | 193 | 6 |
| BIT-314 Drug Profile | 199 | 1 |
| BL-8030 Drug Profile | 200 | 1 |
| BMS-890068 Drug Profile | 201 | 1 |
| BMS-986144 Drug Profile | 202 | 1 |
| BZF-961 Drug Profile | 203 | 1 |
| CC-1845 Drug Profile | 204 | 1 |
| CC-2068 Drug Profile | 205 | 1 |
| CC-2069 Drug Profile | 206 | 1 |
| CC-2850 Drug Profile | 207 | 1 |
| CC-31244 Drug Profile | 208 | 1 |
| CC-31326 Drug Profile | 209 | 1 |
| CDI-244 Drug Profile | 210 | 1 |
| CIGB-230 Drug Profile | 211 | 1 |
| CL-58 Drug Profile | 212 | 1 |
| CRV-431 Drug Profile | 213 | 3 |
| DAG-181 Drug Profile | 216 | 1 |
| danoprevir Drug Profile | 217 | 3 |
| DAPN-PD1 Drug Profile | 220 | 1 |
| DCBF-1 Drug Profile | 221 | 1 |
| DLP-201 Drug Profile | 222 | 1 |
| Drug for Hepatitis C Infections Drug Profile | 223 | 1 |
| Drug to Inhibit NS5A for Hepatitis-C Drug Profile | 224 | 1 |
| Drugs for Hepatitis C Drug Profile | 225 | 1 |
| Drugs to Antagonize Type I Interferon Receptor for Viral Infections Drug Profile | 226 | 1 |
| Drugs to Inhibit NS5B for Hepatitis C Drug Profile | 227 | 1 |
| E-137 Drug Profile | 228 | 1 |
| E-20 Drug Profile | 229 | 1 |
| EDA-NS3 Drug Profile | 230 | 1 |
| EDP-239 Drug Profile | 231 | 1 |
| EDP-494 Drug Profile | 232 | 1 |
| elbasvir + grazoprevir + uprifosbuvir Drug Profile | 233 | 1 |
| emricasan Drug Profile | 234 | 6 |
| faldaprevir Drug Profile | 240 | 6 |
| furaprevir Drug Profile | 246 | 1 |
| Gene Therapy for Hepatitis B and Hepatitis C Drug Profile | 247 | 1 |
| Gene Therapy for Hepatitis C Drug Profile | 248 | 1 |
| glecaprevir Drug Profile | 249 | 1 |
| glecaprevir + pibrentasvir Drug Profile | 250 | 4 |
| GP-205 Drug Profile | 254 | 1 |
| grazoprevir Drug Profile | 255 | 3 |
| GS-563253 Drug Profile | 258 | 1 |
| GSK-2878175 Drug Profile | 259 | 1 |
| GSK-8853 Drug Profile | 260 | 1 |
| H-31356 Drug Profile | 261 | 1 |
| H-5C Drug Profile | 262 | 1 |
| H-5CN Drug Profile | 263 | 1 |
| haprolid Drug Profile | 264 | 1 |
| Hep-1732 Drug Profile | 265 | 1 |
| hepatitis C (strain H77) vaccine Drug Profile | 266 | 1 |
| hepatitis C (virus like particle) vaccine Drug Profile | 267 | 1 |
| hepatitis C (virus-like particle) vaccine Drug Profile | 268 | 1 |
| hepatitis C [serotypes 1a, 1b] vaccine Drug Profile | 269 | 1 |
| hepatitis C vaccine Drug Profile | 270 | 1 |
| hepatitis C vaccine Drug Profile | 271 | 1 |
| hepatitis C vaccine Drug Profile | 272 | 1 |
| hepatitis C vaccine Drug Profile | 273 | 1 |
| hepatitis C vaccine Drug Profile | 274 | 1 |
| hepatitis C vaccine 1 Drug Profile | 275 | 1 |
| hepatitis C virus immune globulin (human) Drug Profile | 276 | 2 |
| HL-143 Drug Profile | 278 | 1 |
| IDX-17119 Drug Profile | 279 | 1 |
| infectious disease vaccine Drug Profile | 280 | 1 |
| INO-8000 Drug Profile | 281 | 2 |
| interferon alfa Drug Profile | 283 | 2 |
| interferon alfa-2a Drug Profile | 285 | 1 |
| interferon alfa-2a SR Drug Profile | 286 | 1 |
| interferon alfa-2b Drug Profile | 287 | 1 |
| interferon alfa-2b Drug Profile | 288 | 1 |
| Interferon Alfa-5 Drug Profile | 289 | 1 |
| JNJ-42039556 Drug Profile | 290 | 2 |
| JNJ-47910382 Drug Profile | 292 | 1 |
| JNJ-56914845 Drug Profile | 293 | 2 |
| KIN-1400 Drug Profile | 295 | 2 |
| KW-001 Drug Profile | 297 | 1 |
| KW-136 Drug Profile | 298 | 1 |
| KW-2 Drug Profile | 299 | 1 |
| KW-5 Drug Profile | 300 | 1 |
| KWO-14 Drug Profile | 301 | 1 |
| KWO-16 Drug Profile | 302 | 1 |
| Lalistat Drug Profile | 303 | 1 |
| LGD-7501 Drug Profile | 304 | 1 |
| MB-110 Drug Profile | 305 | 1 |
| MBL-HCV-1 Drug Profile | 306 | 1 |
| MBX-700 Drug Profile | 307 | 1 |
| MBX-701 Drug Profile | 308 | 1 |
| MCT-465 Drug Profile | 309 | 1 |
| MCT-475 Drug Profile | 310 | 1 |
| miravirsen Drug Profile | 311 | 3 |
| MIV-802 Drug Profile | 314 | 1 |
| MK-1075 Drug Profile | 315 | 1 |
| MK-2248 Drug Profile | 316 | 1 |
| MK-7680 Drug Profile | 317 | 1 |
| Monoclonal Antibodies for Hepatitis C Drug Profile | 318 | 1 |
| Monoclonal Antibodies to Inhibit E2 Glycoprotein for HCV Drug Profile | 319 | 1 |
| Monoclonal Antibodies to Target Claudin 1 for Hepatitis C Drug Profile | 320 | 1 |
| Monoclonal Antibodies to Target Viral E1 and E2 Proteins for Hepatitis C Drug Profile | 321 | 1 |
| Monoclonal Antibody for Hepatitis C Infection Drug Profile | 322 | 1 |
| Monoclonal Antibody to Inhibit E1 and E2 Glycoprotein for Hepatitis C Drug Profile | 323 | 1 |
| Monoclonal Antibody to Target E2 for Hepatitis C Drug Profile | 324 | 1 |
| N-251 Drug Profile | 325 | 1 |
| N-89 Drug Profile | 326 | 1 |
| NA-255 Drug Profile | 327 | 1 |
| naltrexone hydrochloride Drug Profile | 328 | 2 |
| NICAM Program Drug Profile | 330 | 2 |
| NICAM-44002 Drug Profile | 332 | 2 |
| nivocasan Drug Profile | 334 | 1 |
| nivolumab Drug Profile | 335 | 30 |
| NUC-101 Drug Profile | 365 | 1 |
| NVP-018 Drug Profile | 366 | 2 |
| odalasvir Drug Profile | 368 | 6 |
| ombitasvir Drug Profile | 374 | 1 |
| paritaprevir Drug Profile | 375 | 1 |
| pegargiminase Drug Profile | 376 | 7 |
| peginterferon alfa-2a Drug Profile | 383 | 1 |
| peginterferon alfa-2a Drug Profile | 384 | 1 |
| peginterferon lambda-1a Drug Profile | 385 | 1 |
| pibrentasvir Drug Profile | 386 | 1 |
| PPI-383 Drug Profile | 387 | 1 |
| PTC-512 Drug Profile | 388 | 1 |
| PTC-725 Drug Profile | 389 | 1 |
| PTC-971 Drug Profile | 390 | 1 |